A Phase II, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study, Evaluating the Efficacy and Safety of RO4607381 Over a 24-Week Period in Patients With CHD or a CHD Risk Equivalent.

Trial Profile

A Phase II, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study, Evaluating the Efficacy and Safety of RO4607381 Over a 24-Week Period in Patients With CHD or a CHD Risk Equivalent.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jul 2016

At a glance

  • Drugs Dalcetrapib (Primary) ; Atorvastatin
  • Indications Coronary disorders
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 26 Jul 2011 New source identified and integrated (European Clinical Trials Database).
    • 07 Jul 2011 Actual end date (Oct 2008) added as reported by ClinicalTrials.gov.
    • 22 Jan 2010 Results were published in the European Heart Journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top